NovaBone, a calcium-phosphate silicate, is said to be the only synthetic that is osteostimulative, directly increasing the proliferation and activity of osteoblasts, the cells responsible for new bone growth.
This results in more extensive early bone formation than seen for other synthetic graft materials when evaluated during in vivo testing. The FDA has approved the term osteostimulation to describe Nova Bone’s capability.
Arthur Wotiz, CEO of NovaBone Products, said: “Surgeons now have a synthetic that handles more easily. NovaBone bioactive synthetic graft is the only bone graft substitute that has been proven to signal, recruit, proliferate and differentiate osteoblasts. The events culminate in the formation of strong bone fast.”